Pomalidomide

Pomalidomide
Systematic (IUPAC) name
4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 19171-19-8 Y
ATC code None
PubChem CID 134780
UNII D2UX06XLB5 N
ChEMBL CHEMBL43452 N
Chemical data
Formula C13H11N3O4 
Mol. mass 273.24 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Pomalidomide (originally CC-4047), is a derivative of thalidomide and acts as an immunomodulator. It can be taken orally.

Contents

Clinical trials

Phase I trial results showed neutropenia was a frequent side effect.[1]

Phase II clinical trials for multiple myeloma and myelofibrosis have reported 'promising results'.[2][3][4]

Mechanism

The immunomodulatory effect is probably due to inhibition of TNF-alpha with an IC50 of 1 μM. In vitro it affects erythropoeisis[5] and enhances antibody-dependent cellular cytotoxicity (ADCC).[6]

See also

References

  1. ^ Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation, BJH Apr 2008
  2. ^ Promising Results From 2 Trials Highlighting Pomalidomide, Presented At ASH
  3. ^ Promising results from 2 trials highlighting pomalidomide presented at ASH" Dec 2008
  4. ^ Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study
  5. ^ Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells
  6. ^ Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab

External links

Intracellular
(initiation)
Macrolides/
other IL-2 inhibitors
TNF-α inhibitor
Intracellular
(reception)
Extracellular
Serum target
(noncellular)
Cellular target
Unsorted
-cept (Fusion)

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)